



December 16, 2020

PPTA WEBINAR

“UNIQUE PATIENT ACCESS CHALLENGES TO PLASMA-DERIVED MEDICINAL PRODUCTS (PDMPs) THERAPIES IN COVID TIMES”

On behalf of the [Plasma Protein Therapeutics Association](#), we would like to bring to your attention the PPTA webinar "*Unique Patient Access Challenges to Plasma-Derived Medicinal Products (PDMPs) Therapies in COVID Times.*"

Please [click here](#) to watch the webinar.

This webinar aims to identify and address challenges related to patient access in COVID times. It presents PDMPs' societal and economic benefits and discusses how related challenges could be overcome to maximize patient access. Last, the webinar highlights the need that the unique nature of PDMPs is reflected in national policy frameworks.

This panel is composed of:

Mr. Tomasz Kluszczynski, Partner, Vintura

Mr. Oliver Schmitt, General Manager, CSL Behring Italy and
Chair of PPTA's EU Board of Directors

Dr. Frank Willersinn, M.D., President, Alpha-1 PLUS Asbl

Prof. Marcin Czech, Warsaw University of Technology, Poland
and former public authority

Background information

PDMPs are unique biological therapies, derived from human plasma, and used to treat patients with rare, often genetic conditions with high disease burden. Thanks to these treatments, the patient's clinical condition and quality of life improve and productivity increases, demonstrating a health value gain estimated in Europe at 2 billion EUR/year. Some countries have recognized PDMPs' unique value and nature exempting them from economic measures such as clawback/payback taxes. Yet, many countries still apply such measures, threatening the fragile PDMP ecosystem even more so during the pandemic period. COVID highlighted the need for Europe to contribute more to the global plasma collection (overcoming the reliance on the U.S.) and accentuated existing formal and therapeutic patient access challenges to PDMPs. EU Member States should consider strengthening the resilience and management of their healthcare systems and increase patient access to PDMPs by doing what some EU countries did: recognised the unique nature of PDMPs and have lifted, deferred, or reduced such taxes for PDMPs.

About PPTA

The Plasma Protein Therapeutics Association (PPTA – www.pptaglobal.org), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analogue therapies, collectively known as plasma-derived medicinal products (PDMPs). Around 300,000 European patients rely on PDMPs to treat a variety of rare and chronic and/or genetic diseases and serious, often life-threatening medical conditions. For individuals with these conditions, PDMPs replace their missing or deficient proteins. Without these treatments, many patients would either not be able to survive or would have a substantially diminished quality of life and productivity.

For more information, please contact:

[Maarten Van Baelen](#)

Executive Director
PPTA Europe

[Karl Petrovsky](#)

PPTA Director
Health Policy Europe

[Athina Giannoutsou](#)

Manager, Public Affairs
PPTA Europe